ArticleFrontiers in medicine2026
Histopathological spectrum of ocular masses in a tertiary eye center in Northern China: a 12-year retrospective analysis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize the clinicopathological spectrum of ocular masses diagnosed over 12 years at a tertiary referral center in Northern China and identify demographic and regional patterns relevant to clinical practice. Methods: We retrospectively reviewed 1,345 ocular masses diagnosed at Jinan Second People's Hospital between February 2014 and July 2025. Cases were identified from pathology archives and included patients with surgical excision or biopsy and definitive histopathology. Data on age, sex, anatomic location, and mass type were analyzed. Classification followed AFIP atlas standards and ICD-O coding. Results: Of the 1,345 masses, 1,146 (85.2%) were non-malignant and 199 (14.8%) malignant. Lesions were located in the eyelid (35.2%), ocular surface (35.7%), intraocular region (1.8%), and orbit (27.3%). For eyelid masses, nevi (20.8%) and cysts (11.2%) were the most common non-malignant lesions, and basal cell carcinoma (55.6%) and sebaceous gland carcinoma (24.2%) dominated malignancies. For ocular surface masses, the top non-malignant lesions included cysts (20.0%) and inflammatory lesions (18.1%), and malignant melanoma (34.6%) and squamous cell carcinoma (26.9%) were the leading malignancies. Most intraocular masses (20/24) were malignant, and the majority was melanoma (16/20). For orbital masses, hemangiomas (21.1%) were the most frequent benign lesions, and lymphoma (51.9%) was the leading malignancy. The majority of malignancies occurred in patients aged > 60 years (132/199, 66.3%). Compared to patients aged 18-60 years, those aged < 18 years had significantly lower odds of malignancy (OR = 0.21, 95% CI 0.08-0.59), whereas those > 60 years had significantly higher odds of malignancy (OR = 3.29, 95% CI 2.37-4.56). Conclusion: Most ocular masses were non-malignant. The overall risk of malignancy increased significantly after age 60, and this trend was primarily driven by extraocular lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.